Professor Jang Ki-yuk of Seoul St. Mary's Hospital Selected as Basic Research Leader by Ministry of Science and ICT
The Only Leader Researcher in Applied Medicine
Jang Ki-yuk, Professor of Cardiology at the Cardiovascular and Cerebrovascular Hospital, Seoul St. Mary's Hospital, Catholic University of Korea, has been selected as a Type A leader researcher for the 2026 Basic Research Program by the Ministry of Science and ICT.
According to Seoul St. Mary's Hospital on May 28, the leader researcher program is a project that selects world-class science and engineering researchers and provides long-term support for nine years. It is the nation's top-level basic research support program, continuing for nearly 30 years since 1997. Among the 18 leader researchers selected this year, Professor Jang Ki-yuk is the only one in the field of applied medicine to be named. As a Type A researcher, he will receive up to 800 million won per year for nine years, amounting to a total of 7.2 billion won in long-term research funding.
Jang Ki-yook, Professor of Cardiology at the Cardiovascular and Cerebrovascular Center, Seoul St. Mary's Hospital, Catholic University of Korea. Seoul St. Mary's Hospital
View original imageProfessor Jang's research topic is "Next-Generation Therapeutic Strategies for Intractable Cardiovascular Diseases Based on the Induction of Atherosclerotic Plaque Regression." Atherosclerotic plaque is a lesion formed by the accumulation of fats and inflammatory cells on the inner vessel wall and is known as a major cause of cardio-cerebrovascular diseases, including acute myocardial infarction and stroke. According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide, claiming about 18 million lives annually. A significant portion of these deaths arises from acute vascular events caused by the rupture of unstable atherosclerotic plaques. Professor Jang's research team aims not only to stabilize lesions but also to introduce an induction-based approach to selectively regress plaques themselves, presenting a new therapeutic paradigm for intractable cardiovascular diseases that have been beyond the reach of existing treatments.
With nearly 30 years of clinical experience, Professor Jang has led key research in the field of cardiovascular intervention. In 2021, he published the results of the TALOS-AMI study, the largest domestic comparative trial on antiplatelet agents for acute myocardial infarction involving 35 university hospitals and over 3,300 patients, in the prestigious international journal The Lancet. This study provided evidence that a stepwise reduction strategy for antiplatelet therapy after stent implantation in acute myocardial infarction significantly reduces bleeding risk, and has been recognized for its influence on international clinical guidelines.
Subsequently, in 2022, through joint research with the Catholic University College of Medicine team, he and his collaborators were the first in the world to identify a macrophage population expressing the Trem2 gene that suppresses the progression to heart failure after myocardial infarction. These findings were published in the international journal Nature Communications. This research trend, which extends issues identified in the clinical field into basic research, is closely connected to the theme of his current leader research project.
Upon being selected for this research project, Professor Jang stated, "Until now, cardiovascular disease treatment has focused on stabilizing atherosclerotic plaques or resolving vascular stenosis. However, this research is significant in that it aims to selectively remove plaques themselves. I will do my utmost to develop treatment strategies that can be applied to real patients, based on research experience gained at the intersection of basic and clinical medicine."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, since 2012, Professor Jang has performed more than 1,000 cases of transcatheter aortic valve implantation (TAVI), a procedure that replaces the aortic valve using a catheter without opening the chest. In 2021, he also gained acclaim as a clinician in the field of interventional cardiology by successfully performing Korea's first transcatheter caval valve implantation. He has served as Director of the Cardiovascular and Cerebrovascular Hospital at Seoul St. Mary's Hospital and will begin his tenure as president of the Korean Society of Interventional Cardiology (KSIC) starting this September.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.